Should you buy GlaxoSmithKline (GSK) ahead of earnings?
When looking for stocks to buy and hold, safety and stability must be taken into account. Still off its highs, GlaxoSmithKline has a lot more room to grow in share price, and given the dividend cut, its payout should be much more secure as part of a long-term strategy.
What is the price of GSK stock?
GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GSK stock has increased by 16.2% and is now trading at $46.32. View which stocks have been most impacted by COVID-19. When is GlaxoSmithKline's next earnings date?
What are current stock prices?
Price Stock Recommendation; IndusInd Bank: 1019.00: BUY: Buy IndusInd Bank; target of Rs 1387: KR Choksey: Maruti Suzuki: 7641.55: BUY: Buy Maruti Suzuki India; target of Rs 9106: KR Choksey ...
Can we get dividends on shares in the stock market?
Yes, you can get dividends on shares in the stock market. Companies that offer dividends on their shares are generally well-established companies that have a history of rewarding their shareholders. Dividends are rewards that publicly-listed companies provide to their shareholders, and the dividends are provided out of the company’s net profit.
See more
Should I buy or sell GSK stock right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating,...
How has GSK's stock price performed in 2022?
GSK's stock was trading at $44.10 on January 1st, 2022. Since then, GSK stock has decreased by 0.7% and is now trading at $43.80. View the best gr...
Are investors shorting GSK?
GSK saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 6,020,000 shares, a decline of 18.1%...
When is GSK's next earnings date?
GSK is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for GSK .
How were GSK's earnings last quarter?
GSK plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, April, 27th. The pharmaceutical company reported $0.88 earnings per share (E...
How often does GSK pay dividends? What is the dividend yield for GSK?
GSK announced a quarterly dividend on Wednesday, May 4th. Stockholders of record on Friday, May 20th will be given a dividend of $0.3496 per share...
Is GSK a good dividend stock?
GSK(NYSE:GSK) pays an annual dividend of $1.37 per share and currently has a dividend yield of 3.18%. The dividend payout ratio of GSK is 49.46%. T...
Who are GSK's key executives?
GSK's management team includes the following people: Ms. Emma N. Walmsley , CEO & Director (Age 52, Pay $4.88M) Mr. Iain James Mackay , CFO & E...
Who are some of GSK's key competitors?
Some companies that are related to GSK include Eli Lilly and (LLY) , Pfizer (PFE) , Roche (RHHBY) , AbbVie (ABBV) , Merck & Co., Inc. (MRK) ,...
How much is GSK stock worth in 2020?
What is the GSK symbol?
GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GSK stock has decreased by 1.6% and is now trading at $39.23. View which stocks have been most impacted by COVID-19.
What is the dividend payout ratio for GlaxoSmithKline?
GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How much does GlaxoSmithKline make?
Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 69.23% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend. View GlaxoSmithKline's dividend history.
What is the P/E ratio of GlaxoSmithKline?
GlaxoSmithKline has a market capitalization of $105.63 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.98 on an earnings per share basis.
What is GlaxoSmithKline?
The P/E ratio of GlaxoSmithKline is 17.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.33.
When will GlaxoSmithKline release its next quarterly earnings?
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
How many sectors are there in Zacks?
GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021. View our earnings forecast for GlaxoSmithKline.
How many X is Zacks?
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
Is Glaxo a diversified company?
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
Is ZacksTrade a separate company?
The company boasts a diversified base and presence in different geographical areas The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. Glaxo’s new and specialty products are doing well and have become key drivers of top-line growth.
Is Glaxo a JV?
ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
